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populations. By univariate Cox regression analysis, low 
baseline soluble protein levels were associated with lower 
risk of progression/death (all P < 0.05): in both treatment 
arms, baseline VegF-a and Il-8 were associated with 
overall survival (OS) and baseline VegF-C with progres-
sion-free survival (PFS); in the sunitinib arm, baseline 
VegF-a was associated with PFS and baseline sVegFr-3 
with PFS and OS; in the IFn-α arm, baseline Il-8 was 
associated with PFS. In multivariate analysis, baseline 
sVegFr-3 and Il-8 remained independent predictors 
of OS in the sunitinib arm, while no independent predic-
tors of outcome remained in the IFn-α arm. Pharmacody-
namic changes were not associated with PFS or OS for any 
plasma protein investigated.
Conclusions Our findings suggest that, in mrCC, base-
line VegF-a and Il-8 may have prognostic value, while 
baseline sVegFr-3 may predict sunitinib efficacy.
Abstract 
Purpose We investigated potential biomarkers of efficacy 
in a phase III trial of sunitinib versus interferon-alpha (IFn-
α), first-line in metastatic renal cell carcinoma (mrCC), 
by analyzing plasma levels of vascular endothelial growth 
factor (VegF)-a, VegF-C, soluble VegF receptor-3 
(sVegFr-3) and interleukin (Il)-8.
Methods Seven hundred and fifty mrCC patients were 
randomized to oral sunitinib 50 mg/day in repeated cycles 
of a 4-week on/2-week off schedule or IFn-α 9 million 
units subcutaneously thrice weekly. Plasma samples col-
lected from a subset of 63 patients on days 1 and 28 of 
cycles 1–4 and at end of treatment were analyzed by 
elISa.
Results Baseline characteristics of biomarker-evalu-
ated patients in sunitinib (N = 33) and IFn-α (N = 30) 
arms were comparable to their respective intent-to-treat 
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Introduction
the importance of angiogenesis in the growth and progres-
sion of advanced renal cell carcinoma (rCC) has been con-
firmed in the recent past by the success of direct or indi-
rect antiangiogenic treatments in improving the outcome 
of patients with this disease [1–7]. although prognostic 
criteria have been identified which enable classification of 
patients with advanced rCC into good, intermediate and 
poor risk groups [8, 9], the benefits of antiangiogenic ther-
apy have in many cases been shown to span two or more 
of these groups [1, 2, 4, 6, 7]. With an increasing range of 
agents approved for the treatment for advanced rCC, the 
discovery of biological markers that reliably predict and 
help to monitor response to a given agent would assist cli-
nicians in devising individual patient treatment strategies.
Sunitinib malate (SUtent®) is an oral multitargeted 
tyrosine kinase inhibitor with potent activity against vascu-
lar endothelial growth factor receptor (VegFr)-1, -2 and 
-3, platelet-derived growth factor receptor (PDgFr)-α and 
-β, stem cell factor receptor (KIt) and other receptor tyros-
ine kinases, which demonstrates antiangiogenic and anti-
tumor activities [10–12] and is approved for the treatment 
of advanced rCC. In a randomized, multicenter phase III 
trial, sunitinib showed superior progression-free survival 
(PFS; the primary endpoint) to interferon-alpha (IFn-α) as 
first-line therapy of metastatic rCC (mrCC) with median 
PFS of 11 versus 5 months (P < 0.001) [4]. the objective 
response rate (Orr) was also significantly higher in the 
sunitinib arm (Orr 47 vs 12 %; P < 0.001), while median 
overall survival (OS) was 26.4 and 21.8 months in the suni-
tinib and IFn-α arms, respectively (P = 0.051) [4, 13].
Here, we have investigated potential biomarkers of suni-
tinib and IFn-α efficacy in a subset of patients enrolled in 
this phase III trial through the assessment of plasma levels 
of four soluble proteins that are closely linked to the angio-
genesis process: VegF-a, VegF-C, a soluble extracellular 
fragment of VegF receptor-3 (sVegFr-3) and interleu-
kin-8 (Il-8). VegF-a is an endothelial cell-specific mito-
gen that is upregulated in hypoxia through stabilization of 
the transcription factor HIF-1α [14]; this member of the 
VegF family is the primary ligand for VegFr-2 and has 
been shown to mediate angiogenesis in a variety of animal 
models through binding to this receptor [14]. early stud-
ies on VegF-C and its receptor VegFr-3 implicated these 
proteins in the regulation of lymph vessel formation in the 
adult, but more recent research indicates an additional role 
in mediating angiogenesis in a wide range of solid tumors 
[15]. VegFr-3 is highly expressed in angiogenic sprouts 
in a variety of in vivo mouse models and genetic or anti-
body targeting of this receptor inhibits angiogenesis [16], 
while VegF-C induces angiogenesis in the mouse corneal 
pocket assay [17]. Il-8 is a proinflammatory cytokine with 
proliferative and migratory activities in a variety of cell 
types, including tumor cells and endothelial cells [18], 
which stimulates angiogenesis in vivo [19, 20]. In addi-
tion to their roles in the angiogenesis process, these four 
proteins were selected for the present study on the basis of 
the results of prior correlative biomarker studies in rCC, 
suggesting prognostic value for circulating VegF-a [21, 
22], possible predictive or prognostic value for circulating 
VegF-C and sVegFr-3 in patients treated with sunitinib 
[23] and an association between elevated tumor Il-8 mes-




the study population comprised male and female patients 
aged 18 years or over with histologically confirmed mrCC 
with a component of clear cell histology. Key eligibility 
criteria included no previous systemic therapy for rCC; 
measurable disease; eastern Cooperative Oncology group 
(eCOg) performance status 0 or 1; and adequate hepatic, 
renal and cardiac function. additional eligibility criteria 
have been reported previously [4]. all patients gave written 
informed consent.
Study design and treatment
this phase III, multicenter study randomized 750 treat-
ment-naïve patients with mrCC in a 1:1 ratio to receive 
either sunitinib in repeated 6-week cycles or IFn-α; ran-
domization was stratified as previously described [4]. the 
study was run in accordance with provisions of the Dec-
laration of Helsinki and good Clinical Practice guidelines 
and was approved by the institutional review board or inde-
pendent ethics committee of each participating center.
Sunitinib was administered orally at 50 mg/day for 
4 weeks, followed by 2 weeks off treatment (schedule 4/2). 
IFn-α was administered as a subcutaneous injection on 3 
non-consecutive days per week, starting at 3 million units 
(MU) for the first week, 6 MU for the second week and 9 
MU thereafter. treatment continued until disease progres-
sion, unacceptable toxicity or withdrawal of consent. the 
primary end point was progression-free survival (PFS). 
tumor response and progression were determined accord-
ing to the response evaluation Criteria in Solid tumors 
(reCISt) [25], based on central radiology review of the 
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data. tumor assessments were performed at screening, on 
day 28 of cycles 1–4 and of every 2 cycles thereafter, and 
at the end of treatment, to confirm a response or if disease 
progression was suspected. an exploratory biomarker com-
ponent of the study was undertaken at a limited number of 
participating sites.
assessment of biomarkers
the centers that participated in this correlative biomarker 
substudy were selected on a voluntary basis, driven by the 
scientific interest of investigators as well as the availability 
of suitable operational capabilities. Plasma samples were 
collected from all patients enrolled at the participating cent-
ers prior to dosing on days 1 and 28 of cycles 1–4 and at the 
end of treatment. Plasma samples were stored at −70 °C 
until required for analysis, and the duration of storage was 
within the period covered by stability evaluation. Plasma 
protein levels were analyzed for VegF-a, VegF-C, 
sVegFr-3 and Il-8 using validated enzyme-linked immu-
nosorbent assay (elISa) kits (r&D Systems, Minneapo-
lis, Mn). the VegF-a elISa measures the VegF-a165 
and VegF-a121 isoforms; the sVegFr-3 kit measures the 
extracellular (soluble) domain of VegFr-3. assays were 
conducted following the manufacturer’s instructions except 
in the case of sVegFr-3, for which sample dilution was 
1:10 rather than 1:100 in order to increase assay sensitivity. 
all assays were run under good laboratory Practice condi-
tions, and performance specifications of each elISa were 
validated for their intended purpose per established guide-
lines [26].
Statistical analysis
Soluble protein biomarker data were summarized using 
descriptive statistics. assay results that were below the 
limit of quantitation (BlQ) and samples that were missing 
at time points prior to study discontinuation were excluded 
from the analysis. to evaluate the significance of changes 
in plasma protein concentrations from baseline at each 
time point, arithmetic differences (concentration at cycle 
X day Y − concentration at cycle 1 day 1) were analyzed 
using the Wilcoxon signed-rank test. Median PFS and OS 
values were estimated by the Kaplan–Meier method after 
stratification by the median baseline protein concentra-
tion or by the median ratio to baseline at each time point, 
and curves were compared using the log-rank test. Poten-
tial correlations between soluble protein values or baseline 
characteristics and PFS or OS were assessed by univariate 
and multivariate analyses using the Cox proportional haz-
ards model and the Wald test. the baseline characteristics 
investigated were age; sex; number of disease sites (<3 vs 
≥3); eCOg performance status (0 vs 1); nephrectomy (yes 
vs no); time since diagnosis (<1 vs ≥1 year); and number 
of risk factors (0 vs 1 or 2) as identified and published by 
the Memorial Sloan-Kettering Cancer Center (MSKCC; 
risk factors comprise low serum hemoglobin level; elevated 
corrected serum calcium level; elevated serum lactate dehy-
drogenase level; poor performance status; and interval of 
<1 year between diagnosis and treatment) [8]. Since the 
plasma proteins evaluated here were selected based on the 
evidence of predictive or prognostic value obtained in prior 
correlative studies, the present analysis evaluated specific 
biomarker hypotheses and adjustments for multiple com-
parisons were not applied.
Results
Comparison between biomarker subset and intent-to-treat 
populations
Plasma samples were collected, and protein biomarkers 
were measured in patients in the sunitinib (N = 33) and 
IFn-α (N = 30) arms who were enrolled at selected sites in 
this phase III study. Baseline characteristics were broadly 
comparable between biomarker-evaluated patients and 
their respective intent-to-treat (Itt) populations (table 1), 
although the biomarker subset tended to have less extensive 
disease than the Itt population.
as in the Itt population [4, 13], patients in the bio-
marker subset receiving sunitinib had significantly longer 
PFS than those receiving IFn-α [median PFS 13.7 vs 
5.1 months; hazard ratio 0.293 (95 % confidence interval 
or CI 0.129–0.665); P = 0.0021]; sunitinib patients in the 
biomarker subset also showed a trend for improved OS 
compared with IFn-α patients [median OS not reached 
vs 18.3 months; hazard ratio 0.509 (95 % CI 0.246–1.05); 
P = 0.0626].
Baseline plasma protein levels and ratios to baseline 
on treatment with sunitinib or interferon-α
none of the assay results for VegF-a or sVegFr-3 were 
BlQ, while the proportion of assay results for VegF-
C and Il-8 that were BlQ was 0.52 and 0.78 %, respec-
tively. Median baseline plasma VegF-a concentrations in 
both the sunitinib arm (49.2 pg/ml, N = 33) and the IFn-α 
arm (53.1 pg/ml, N = 30) were significantly higher than 
median VegF-a levels in healthy volunteers (14.8 pg/ml, 
N = 15; P < 0.0001 in each case). Similarly, median base-
line plasma VegF-C concentrations in both the sunitinib 
arm (493.7 pg/ml, N = 33) and the IFn-α arm (503.3 pg/
ml, N = 30) were significantly higher than median 
VegF-C levels in healthy volunteers (207.6 pg/ml, 
N = 19; P < 0.0001 in each case). Median baseline plasma 
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sVegFr-3 concentrations in the sunitinib arm (38.9 ng/
ml, N = 33) and the IFn-α arm (37.6 ng/ml, N = 30), 
and median baseline Il-8 concentrations in the sunitinib 
arm (7.0 pg/ml, N = 31) and the IFn-α arm (9.5 pg/ml, 
N = 29) did not differ significantly from median base-
line levels of sVegFr-3 (43.6 ng/ml, N = 20) and Il-8 
(6.5 pg/ml, N = 20) in healthy volunteers. In no case did 
baseline plasma protein concentrations in the sunitinib arm 
differ significantly from those in the IFn-α arm.
In the sunitinib arm, median plasma levels of VegF-a 
increased reversibly compared with baseline by more than 
fourfold during treatment, while those of Il-8 increased 
by approximately twofold to threefold on treatment and 
showed less reversibility than VegF-a after 2-week off-
drug periods (Fig. 1); median increases from baseline lev-
els were significant in all cases. Changes in median plasma 
VegF-C levels during treatment were minimal, while 
median sVegFr-3 levels decreased reversibly and signifi-
cantly by approximately 50 %. In the IFn-α arm, plasma 
Il-8 levels were significantly elevated approximately two-
fold above baseline on study, while levels of the other pro-
teins did not change (Fig. 1).
relationship between soluble protein levels and efficacy 
end points
Comparison of Kaplan–Meier time-to-event curves after 
patient stratification by median baseline soluble protein 
concentrations showed that, in the sunitinib arm, patients 
with baseline VegF-a levels below the median had sig-
nificantly longer PFS than those with baseline VegF-a 
greater than or equal to the median (median PFS 13.7 vs 
7.8 months; P = 0.0059; table 2); OS was also signifi-
cantly improved in patients with baseline VegF-a below 
the median (median OS not reached vs 21.8 months; 
P = 0.0043; table 2). Similar results were obtained for 
baseline sVegFr-3 in sunitinib-treated patients (Fig. 2), 
although the difference in OS did not reach significance 
Table 1  Baseline 
characteristics in the biomarker 
subset and the intent-to-treat 
population, by treatment arm
ECOG eastern Cooperative 





 By local regulation
b
 Data were missing for 17 
patients in the IFn-α group 
(including one patient in the 
biomarker subset). Includes 
low serum hemoglobin level; 
elevated corrected serum 
calcium level; elevated serum 
lactate dehydrogenase level; 
poor performance status; and 
interval of <1 year between 














 Male 21 (64) 24 (80) 267 (71) 269 (72)
 Female 12 (36) 6 (20) 108 (29) 106 (28)
race, n (%)
 White 32 (97) 25 (83) 354 (94) 340 (91)
 Black 0 1 (3) 4 (1) 9 (2)
 asian 1 (3) 2 (7) 7 (2) 12 (3)
 not listed 0 2 (7) 9 (2) 13 (3)
 not allowed to aska 0 0 1 (<1) 1 (<1)
Median age (range), years 64 (40–87) 62 (42–85) 62 (27–87) 59 (34–85)
eCOg performance status, n (%)
 0 25 (76) 20 (67) 231 (62) 229 (61)
 1 8 (24) 10 (33) 144 (38) 146 (39)
Prior nephrectomy, n (%) 29 (88) 27 (90) 337 (90) 336 (90)
Sites of metastasis, n (%)
 lung 26 (79) 24 (80) 292 (78) 297 (79)
 liver 10 (30) 12 (40) 99 (26) 90 (24)
 Bone 5 (15) 7 (23) 113 (30) 112 (30)
 lymph node 20 (61) 16 (53) 218 (58) 198 (53)
number of disease sites, n (%)
 1 6 (18) 9 (30) 54 (14) 73 (19)
 2 12 (36) 8 (27) 107 (29) 111 (30)
 ≥3 15 (45) 13 (43) 214 (57) 191 (51)
risk factors based on published MSKCC data,b n (%)
 0 (favorable) 11 (33) 12 (41) 143 (38) 121 (34)
 1–2 (intermediate) 22 (67) 17 (59) 209 (56) 212 (59)
 ≥3 (poor) 0 0 23 (6) 25 (7)
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(table 2). In the IFn-α arm, patients with baseline Il-8 
below median levels had significantly longer PFS and a 
trend for longer OS than those with baseline Il-8 greater 
than or equal to the median (median PFS 7.8 vs 2.6 months; 
P = 0.0472; table 2). When PFS was compared between 
the sunitinib and IFn-α arms in patient subsets having 
relatively low (below the median) or relatively high (greater 
than or equal to the median) baseline levels of each solu-
ble protein, hazard ratios favored sunitinib in all analyses. 
In each case, the treatment effect was greater for patients 
with relatively low soluble protein levels at baseline 
(table 3). there were no significant associations between 
Fig. 1  Change in biomarker [vascular endothelial growth fac-
tor (VegF)-a, VegF-C, interleukin-8 (Il-8) and soluble vascular 
endothelial growth factor receptor-3 (sVegFr-3)] levels during treat-
ment in the a sunitinib arm and b interferon-alpha arm. *P < 0.05; 
**P < 0.01; ***P < 0.0001 compared with baseline
Table 2  Within-treatment comparison of progression-free and overall survival stratified by median baseline soluble protein concentrations
CI confidence interval, HR hazard ratio, IL-8 interleukin-8, IFN-α interferon-alpha, NR not reached, PFS progression-free survival, OS overall 
survival, VEGF-A vascular endothelial growth factor a, VEGF-C vascular endothelial growth factor C, sVEGFR-3 soluble vascular endothelial 
growth factor receptor 3
a
 total N = 33 and N = 30 for each protein in the sunitinib and IFn-α arms, respectively, apart from Il-8, where total N = 31 and N = 29 in the 
sunitinib and IFn-α arms, respectively
Soluble protein treatment arma Median PFS (months) Hr (95 % CI) log-rank P
<Median [protein] ≥Median [protein]
VegF-a Sunitinib 13.7 7.8 2.55 (1.19–5.48) 0.0059
IFn-α 7.8 3.9 1.35 (0.805–2.27) 0.248
VegF-C Sunitinib 13.7 11.1 1.42 (0.779–2.59) 0.242
IFn-α 5.1 7.8 1.12 (0.619–2.01) 0.713
sVegFr-3 Sunitinib 21.7 10.9 2.40 (1.13–5.11) 0.0104
IFn-α 5.4 3.9 1.16 (0.688–1.95) 0.582
Il-8 Sunitinib 21.7 12.4 1.20 (0.685–2.1) 0.524
IFn-α 7.8 2.6 1.84 (1.055–3.47) 0.0472
Plasma protein treatment arma Median OS (months) Hr (95 % CI) log-rank P
<Median [protein] ≥Median [protein]
VegF-a Sunitinib nr 21.8 2.60 (1.22–5.53) 0.0043
IFn-α 26.6 12.8 1.49 (0.903–2.45) 0.11
VegF-C Sunitinib nr 23.3 1.51 (0.837–2.72) 0.159
IFn-α 22.0 16.5 1.01 (0.619–1.66) 0.961
sVegFr-3 Sunitinib nr 23.3 1.68 (0.928–3.04) 0.0738
IFn-α 22.0 17.6 1.24 (0.757–2.04) 0.388
Il-8 Sunitinib nr 23.3 1.37 (0.761–2.48) 0.283
IFn-α 22.0 12.9 1.52 (0.924–2.51) 0.0897
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pharmacodynamic changes in the soluble proteins investi-
gated and either PFS or OS (data not shown).
Baseline plasma protein concentrations and ratio to base-
line values (expressed as continuous variables) and baseline 
clinical characteristics were also analyzed using the Cox 
proportional hazards model. For each soluble protein ana-
lyzed, low plasma concentrations at baseline were associ-
ated with a lower risk of progression and death (table 4). 
In univariate analysis for both treatment arms, baseline 
VegF-a, Il-8 and prior nephrectomy correlated with OS 
while baseline VegF-C correlated with PFS (table 4). In 
the sunitinib arm, baseline VegF-a correlated with PFS, 
and baseline sVegFr-3 correlated with both PFS and OS. 
In the IFn-α arm, baseline Il-8 and prior nephrectomy also 
correlated with PFS, while number of disease sites corre-
lated with OS (table 4). In multivariate analysis, only base-
line sVegFr-3 and baseline Il-8 were significant predic-
tors of OS in the sunitinib arm, while none were significant 
in the IFn-α arm (table 4).
Discussion
In this study, we have investigated the plasma pharmaco-
dynamics of a panel of circulating proteins linked to the 
mechanism of action of sunitinib (VegF-a, VegF-C, 
sVegFr-3), as well as Il-8, a potential mediator of resist-
ance to VegFr inhibition, in a subset of patients in a ran-
domized phase III study comparing sunitinib and IFn-α 
as first-line treatment for mrCC. In addition, we have 
explored possible associations between baseline levels 
of these proteins, or changes from baseline at each time 
point, and clinical outcome. Significant and consistent 
changes from baseline levels were seen for plasma VegF-
a, Il-8 and sVegFr-3 in the sunitinib arm and for plasma 
Il-8 in the IFn-α arm. In both treatment arms, baseline 
Fig. 2  Sunitinib arm: a progression-free and b overall survival after stratification by median baseline plasma soluble vascular endothelial 
growth factor receptor-3 (sVegFr-3)
Table 3  Comparison of progression-free survival between sunitinib 
and interferon-alpha arms in patient subsets having relatively low 
(<median) or high (≥median) baseline levels of each soluble protein
CI confidence interval, HR hazard ratio, IL-8 interleukin-8, IFN-α 
interferon-alpha, PFS progression-free survival, VEGF-A vascular 
endothelial growth factor a, VEGF-C vascular endothelial growth 
factor C, sVEGFR-3 soluble vascular endothelial growth factor recep-
tor 3
a
 total N = 33 and N = 30 for each protein in the sunitinib and IFn-
α arms, respectively, apart from Il-8, where total N = 31 and N = 29 
in the sunitinib and IFn-α arms, respectively
Patient subseta Median PFS 
(months)
Hr (95 % CI) log-rank P
Sunitinib IFn-α
VegF-a
 <Median 13.7 7.8 0.148 (0.038–0.579) 0.0019
 ≥Median 10.9 3.9 0.451 (0.149–1.36) 0.150
VegF-C
 <Median 13.7 5.1 0.190 (0.059–0.617) 0.0022
 ≥Median 11.1 7.8 0.551 (0.156–1.94) 0.348
sVegFr-3
 <Median 21.7 5.4 0.122 (0.024–0.615) 0.0034
 ≥Median 10.9 3.9 0.406 (0.147–1.12) 0.0719
Il-8
 <Median 21.7 7.8 0.247 (0.077–0.787) 0.0114
 ≥Median 13.7 2.6 0.403 (0.12–1.35) 0.131
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Table 4  Univariate and multivariate analyses of progression-free survival and overall survival by treatment arm using the Cox proportional haz-
ards model
For binary variables, a hazard ratio <1 represents risk reduction for the first category and a hazard ratio >1 represents risk reduction for the 
second category; for continuous variables (i.e., the soluble proteins), a hazard ratio >1 equates to risk reduction when the value decreases and a 
hazard ratio <1 equates to risk reduction when the value increases
Variables that were significant (P < 0.05) by univariate analysis were evaluated in the multivariate model
CI confidence interval, ECOG eastern Cooperative Oncology group, HR hazard ratio, MSKCC Memorial Sloan-Kettering Cancer Center, PFS 
progression-free survival, OS overall survival
a
 Includes low serum hemoglobin level; elevated corrected serum calcium level; elevated serum lactate dehydrogenase level; poor performance 
status; and interval of <1 year between diagnosis and treatment [8]
Variables [n for each group] PFS OS
Hr (95 % CI) Wald P Hr (95 % CI) Wald P
Sunitinib
 Univariate analysis
  age (<65 vs ≥65 years) [17, 16] 0.595 (0.179–1.99) 0.3990 0.698 (0.228–2.14) 0.5290
  Sex (M vs F) [21, 12] 0.893 (0.267–2.99) 0.8540 0.779 (0.24–2.53) 0.6780
  no. of disease sites (<3 vs ≥3) [18, 15] 1.16 (0.383–3.47) 0.7950 2.12 (0.694–6.51) 0.1870
  eCOg performance status (0 vs 1) [25, 8] 1.58 (0.474–5.26) 0.4540 2.37 (0.773–7.25) 0.1310
  nephrectomy (no vs yes) [4, 29] 0.269 (0.071–1.02) 0.0531 0.197 (0.053–0.729) 0.0150
  time since diagnosis (<1 vs ≥1 year) [21, 12] 0.301 (0.066–1.37) 0.1210 0.274 (0.061–1.24) 0.0921
  risk factors based on published MSKCC dataa (0 vs 1 
or 2) [11, 22]
2.74 (0.599–12.5) 0.1940 6.84 (0.888–52.6) 0.0649
  Baseline VegF-a (ng/10 ml) [33] 1.28 (1.06–1.55) 0.0108 1.33 (1.09–1.63) 0.0052
  Baseline VegF-C (ng/ml) [33] 6.42 (1.25–33) 0.0259 2.91 (0.703–12.1) 0.1410
  Baseline sVegFr-3 (ng/ml) [33] 1.04 (1.01–1.06) 0.0026 1.04 (1.02–1.07) 0.0012
  Baseline Il-8 (pg/ml) [31] 1.05 (0.991–1.11) 0.1010 1.08 (1.03–1.14) 0.0026
 Multivariate analysis
  nephrectomy (no vs yes) [4, 29] – – 0.385 (0.065–2.28) 0.290
  Baseline VegF-a (ng/10 ml) [33] 1.05 (0.677–1.63) 0.82 0.559 (0.310–1.01) 0.053
  Baseline VegF-C (ng/ml) [33] 4.84 (0.665–35.23) 0.12 – –
  Baseline sVegFr-3 (ng/ml) [33] 1.03 (0.975–1.09) 0.300 1.064 (1.004–1.13) 0.037
  Baseline Il-8 (pg/ml) [31] – – 1.110 (1.022–1.20) 0.013
Interferon-alpha
 Univariate analysis
  age (<65 vs ≥65 years) [16, 14] 3.87 (0.967–15.5) 0.0558 1.21 (0.454–3.23) 0.7040
  Sex (M vs F) [24, 6] 1.36 (0.347–6.89) 0.7220 1.92 (0.612–6.02) 0.2640
  no. of disease sites (<3 vs ≥3) [17, 13] 1.16 (0.408–3.31) 0.7780 3.78 (1.39–10.3) 0.0092
  eCOg performance status (0 vs 1) [20, 10] 1.88 (0.656–1.39) 0.2400 2.05 (0.735–5.7) 0.1700
  nephrectomy (no vs yes) [3, 27] 0.06 (0.008–0.418) 0.0049 0.09 (0.018–0.478) 0.0044
  time since diagnosis (<1 vs ≥1 year) [14, 16] 1.18 (0.404–3.44) 0.7630 0.68 (0.252–1.83) 0.4450
  risk factors based on published MSKCC dataa  
(0 vs 1 or 2) [12, 17]
0.77 (0.268–2.22) 0.6310 1.99 (0.631–6.27) 0.2410
  Baseline VegF-a (ng/10 ml) [30] 3.05 (0.48–19.4) 0.237 1.24 (1.04–1.47) 0.0174
  Baseline VegF-C (ng/ml) [30] 3.64 (1.22–10.9) 0.0206 2.12 (0.917–4.89) 0.0790
  Baseline sVegFr-3 (ng/ml) [30] 1.01 (0.971–1.06) 0.5270 1.04 (1–1.08) 0.0505
  Baseline Il-8 (pg/ml) [29] 1.04 (1–1.07) 0.0423 1.02 (1–1.03) 0.0094
 Multivariate analysis
  no. of disease sites (<3 vs ≥3) [17, 13] – – 2.428 (0.752–7.84) 0.140
  nephrectomy (no vs yes) [3, 27] 0.113 (0.008–1.52) 0.100 0.218 (0.028–1.67) 0.140
  Baseline VegF-a (ng/10 ml) [30] – – 0.925 (0.525–1.63) 0.790
  Baseline VegF-C (ng/ml) [30] 1.470 (0.158–13.6) 0.740 – –
  Baseline Il-8 (pg/ml) [29] 1.018 (0.964–1.08) 0.520 1.013 (0.969–1.06) 0.560
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levels of plasma VegF-a, VegF-C and Il-8 were signifi-
cantly associated with PFS or OS, while baseline plasma 
sVegFr-3 was significantly associated with PFS and OS 
in the sunitinib arm only. no significant and consistent cor-
relations were seen between plasma protein changes from 
baseline and clinical outcome in either treatment arm.
Our findings provide additional support for the hypoth-
esis that circulating VegF-a is prognostic for OS in 
rCC, with low baseline concentrations of VegF-a cor-
relating with longer OS in both sunitinib and IFn-α arms 
in the present study. Consistent with these results, Peña 
et al. [21] observed that low baseline serum VegF-a lev-
els in the placebo arm correlated with longer OS by uni-
variate analysis in a placebo-controlled phase III study 
of sorafenib, a multitargeted kinase inhibitor with potent 
activity against the 3 VegF receptors. as observed here, 
significance was not seen by multivariate analysis when 
other circulating biomarkers were included. also, no cor-
relations were observed between the change in biomarker 
levels (from baseline to week 3 or 12) and outcome (PFS 
or OS) in sorafenib-treated patients. With respect to PFS in 
sunitinib-treated rCC patients, our finding of an associa-
tion between low baseline VegF-a and prolonged PFS is 
similar to that reported by Porta et al. [27] in a biomarker 
study from the sunitinib expanded access program; assess-
ment of potential correlations with OS was not included 
in that study. although rini et al. [23] did not observe a 
correlation between baseline VegF-a levels and PFS in 
a phase II study of sunitinib in mrCC patients refractory 
to the anti-VegF-a antibody bevacizumab, this negative 
result may have been influenced by prior VegF-a path-
way inhibition by bevacizumab in this patient population, 
or by the confounding effects of residual bevacizumab in 
plasma samples on antibody-based VegF-a measurement 
by elISa. In that phase II sunitinib study, baseline VegF-
a concentrations were inversely correlated with time since 
final bevacizumab treatment. Other studies in rCC patients 
have linked high baseline VegF-a concentrations with 
shorter survival time, higher clinical stage and higher tumor 
grade [28–30] and, in some cases, have identified baseline 
VegF-a as an independent prognostic factor for PFS and/
or OS [22, 31].
the phase II sunitinib rCC study cited earlier that 
involved patients refractory to bevacizumab [23] demon-
strated an association between low baseline sVegFr-3 
concentrations and prolonged PFS, consistent with the 
association reported here for the sunitinib arm. the 
absence of a significant association between sVegFr-3 
and either PFS or OS in the IFn-α arm of the present 
study, although trending toward significance for OS, sug-
gests that sVegFr-3 may be more predictive of sunitinib 
efficacy than prognostic in rCC, but more research is nec-
essary to address this question. early reports implicated 
VegFr-3 exclusively in the process of lymph vessel pro-
duction (lymphangiogenesis), but more recent studies have 
shown that this receptor for VegF-C and VegF-D (but not 
VegF-a) is expressed both in tumor lymph vessels and in 
tumor endothelium in a variety of malignancies [32–34]. 
although lymphangiogenic activity appears to be relatively 
low in clear cell rCC [35, 36], our correlative findings 
for sVegFr-3 suggest a possible role for the inhibition 
of lymphangiogenesis in the clinical activity of sunitinib 
in this disease, in addition to antiangiogenesis. Further 
research is required to distinguish between these possibili-
ties. also of interest is the recent paper by garcia-Donas 
et al. [37], which reported strong associations between two 
VegFr3 polymorphisms and PFS in rCC patients treated 
with sunitinib. taken together, these findings strongly 
implicate VegFr-3 as a potential target for sunitinib that 
may contribute to efficacy in patients with mrCC.
Il-8 (CXCl8) is a CXC family chemokine that activates 
multiple signaling pathways, increases proliferation and 
survival of both endothelial and tumor cells and facilitates 
the migration of these cell types [18]. In addition, Il-8 pos-
sesses potent proangiogenic activity in vivo [19, 20]. tumor 
Il-8 expression is upregulated in rCC and has been associ-
ated both with more advanced disease and with poor sur-
vival [24, 38, 39]. Consistent with these published reports, 
the present findings suggest that high baseline plasma 
levels of Il-8 are associated with poor prognosis in rCC; 
plasma Il-8 concentrations correlated inversely with OS in 
both treatment arms and correlated inversely with PFS in 
the IFn-α arm, remaining an independent predictor of OS 
in the sunitinib arm. Studies with the potent VegF receptor 
inhibitor pazopanib have also shown that Il-8 is prognostic 
for outcome in rCC, as well as predictive of response [40, 
41]. Preclinically, Il-8 has recently been shown to mediate 
sunitinib resistance in animal models of rCC [42]. these 
investigators found that sunitinib-resistant renal tumors 
were more highly vascularized than those that were sen-
sitive and hypothesized that the tumors had escaped from 
the antiangiogenic effects of sunitinib by activation of a 
VegF/VegFr-independent mechanism. Screening of 
xenograft-bearing mice for changes in plasma levels of 89 
angiogenic factors revealed that human Il-8 levels were 
significantly elevated in sunitinib-resistant mice, while lev-
els of human VegF-a (and other factors) were unchanged. 
Furthermore, neutralization of Il-8 activity partially 
restored sunitinib sensitivity in these preclinical models. In 
a small prospective study, the same authors also found that 
baseline Il-8 expression was significantly higher in tumor 
specimens from rCC patients with intrinsic resistance to 
sunitinib than in tumor specimens from patients who did 
not progress on treatment. Overall, preclinical and clini-
cal investigations have provided in vivo evidence of a role 
for Il-8 as a mediator of tumor progression in rCC and 
159Cancer Chemother Pharmacol (2014) 73:151–161 
1 3
as a possible mechanism of innate or acquired resistance to 
antiangiogenic therapy in this disease.
Plasma Il-8 levels were significantly elevated above 
baseline at all time points in both arms of this randomized 
study. Hypoxia has been shown to upregulate Il-8 expres-
sion in human rhabdomyosarcoma cell lines, in a man-
ner that is independent of HIF-1α activity [43]. a similar 
mechanism might account for plasma Il-8 induction in 
the present study, even in the presence of VegF receptor 
blockade in sunitinib-treated patients. although hypoxia 
also induces Il-8 expression in cultured endothelial cells 
[44], this response is mediated by VegF-a and is there-
fore unlikely to account for elevated plasma Il-8 lev-
els following sunitinib treatment. In vivo evidence for 
hypoxia-induced Il-8 expression was obtained in D-12 
melanoma xenografts, in which Il-8 expression was seen 
in vascular hot spots that were associated with hypoxic 
foci [45]. In support of a role for hypoxia in Il-8 induc-
tion in the IFn-α arm, IFn-α has been shown to possess 
antiangiogenic activity [46, 47], in addition to its immu-
nomodulatory properties. However, the finding that plasma 
VegF-a levels did not significantly change in response 
to IFn-α treatment, whereas a marked and significant 
increase in VegF-a from baseline levels was seen at the 
end of each treatment period in the sunitinib arm, sug-
gests that a mechanism other than hypoxia induction may 
be involved in plasma Il-8 induction in IFn-α-treated 
patients. Clearly, further research is required to explore 
possible mechanism(s) underlying plasma Il-8 pharmaco-
dynamics in the present study.
accumulating data suggests an influence of germline 
polymorphisms on rCC patient efficacy and safety when 
receiving targeted anti-VegF or VegFr2 tyrosine kinase 
inhibitor therapies. Specifically, publications have cited 
polymorphisms in the VegF-a gene [48] or VegFr-3 
as associating with clinical outcome [49]. However, the 
absence of concordance of findings, different SnPs assayed 
and endpoints measured preclude use of germline polymor-
phism data for patient selection at the current time. large 
multicenter prospective rCC studies in which baseline 
characteristics, clinical outcomes and SnPs are measured 
will allow for unequivocal assignment of utility of SnPs 
for patient selection.
a number of limitations apply to the present investiga-
tion. Firstly, only selected sites participated in the explora-
tory biomarker component of this pivotal phase III study. 
as a result, samples sizes in the sunitinib and IFn-α arms 
(33 and 30, respectively, at baseline) were small in rela-
tion to patient numbers in the corresponding Itt popula-
tions (less than 10 % in each case). the power to detect 
significant correlations between plasma proteins and clini-
cal outcome was thus markedly reduced, and the possibility 
of type II errors was markedly increased, when compared 
with a biomarker analysis involving all patients on study. 
nonetheless, a number of significant associations with 
PFS or OS were observed for soluble proteins in pretreat-
ment plasma samples, and it should be noted that baseline 
characteristics and clinical outcome (PFS, OS) for the bio-
marker-evaluated patient subsets in the two treatment arms 
were a good representation of their respective full study 
populations. another limitation of this study is that we have 
focused on a small panel of circulating proteins, yet there 
are many proteins not directly linked to sunitinib’s molecu-
lar mechanism, of which Il-8 is but one example, that have 
the potential to predict resistance to sunitinib therapy in 
rCC based on a known regulatory role in angiogenesis. 
Circulating biomarkers, including plasma proteins, have 
the distinct practical advantage of relatively facile sam-
pling and quantitative analysis when compared with tumor 
tissue-based end points. However, the search for circulat-
ing proteins with utility in clinical decision-making for any 
approved agent in rCC, or indeed any other tumor type, 
has proven largely unsuccessful, likely in part because the 
data collected often reflect systemic processes to a greater 
extent than the relevant tumor biology. Finally, we have 
interpreted significant associations that were obtained for 
OS in both treatment arms to suggest prognostic rather 
than predictive value for a biomarker. However, since the 
efficacy of IFn-α in rCC may be mediated in part by 
angiogenesis inhibition, prediction of survival for such a 
biomarker may not be entirely independent of treatment 
modality.
In summary, the present investigation provides evidence 
that plasma concentrations of VegF-a and Il-8 may be 
prognostic for OS in mrCC, with high levels being unfa-
vorable. In addition, low plasma levels of the soluble form 
of VegFr-3 may predict improved outcome for rCC 
patients receiving sunitinib, suggesting that inhibition of 
angiogenesis and/or lymphangiogenesis mediated by this 
VegF receptor family member may contribute to the effi-
cacy of this potent multitargeted tyrosine kinase inhibitor. 
Further predictive biomarker research is clearly warranted 
in mrCC, not only for sunitinib but also for other VegF 
pathway inhibitors and for agents targeting other pathways.
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